We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Association of Clinical Research Professionals (ACRP) and the American Academy of Pharmaceutical Physicians (AAPP) have merged to create a professional medical society that will unify, certify and educate clinical researchers.
Biogen Idec and Protein Design Labs (PDL) have announced plans to collaborate on the joint development, manufacture and commercialization of three Phase II antibody products to treat various diseases such as multiple sclerosis and cancer.
Generic powerhouse Teva Pharmaceutical reported $241 million in net income and $1.23 billion in net sales during the second quarter, an increase of 5 percent and 4 percent respectively over the same period last year, according to the firm’s earnings report.
David Brennan will become CEO of AstraZeneca on Jan. 1, 2006, replacing Tom McKillop, who will step down at the end of this year, the company announced July 28 as it reported its second quarter financial results.
Former New York City Mayor Rudy Giuliani is calling for a moratorium on drug importation legislation, warning that terrorists could use such a system as a vehicle for attacking the U.S.
Geneva-based Serono has discontinued two Phase III clinical trial programs on the recommendations of two independent data and safety monitoring boards, the company announced April 6.
Maxygen and Roche are completing late-stage preclinical studies and manufacturing on their collaborative effort to develop improved interferon alpha protein therapeutics to treat hepatitis C virus (HCV) and hepatitis B virus (HBV) infections, and they expect to file an investigational new drug application toward Phase I clinical trials next year, Maxygen said.
Amid the growing uncertainty about the safety of Cox-2 inhibitors, Pfizer has agreed to delay the European launch of Onsenal, a Cox-2 drug approved in the EU for the treatment of intestinal polyps.